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Abstract 
Background: The containment of artemisinin resistance in Myanmar, historically an important probable origin and 
route of anti-malarial resistance to the India sub-continent and beyond, is crucial to global malaria control and elimi-
nation. This paper describes what is currently known about the sale and distribution of oral artemisinin monotherapy 
(AMT) across Myanmar, where this medicine is commonly found.
Methods: A nationally representative 2015 outlet survey was conducted in the private sector, and among commu-
nity health workers across four geographical domains. A national sample of outlets was screened for availability of 
malaria testing and treatment, and an audit was completed for all anti-malarials.
Results: A total of 3859 outlets across Myanmar had an anti-malarial in stock on the day of survey. Of the 3859 
anti-malarial stocking outlets, 988 outlets stocked oral AMT. Availability of oral AMT was highest among outlets in the 
Western border (36.8%) versus other domains (Eastern, 15.0%; Central, 19.3% Coastal, 10.7%). Over 90% of the oral 
AMT service delivery points were private sector outlets: general retailers (49.4%), pharmacies (23.5%), and itiner-
ant drug vendors (14.2%). Eleven unique oral AMT products were audited. The most common product audited was 
 Artesunate®, manufactured by Mediplantex in Vietnam, which accounted for 79.9% of the oral AMT market share. 
Other oral AMT products were manufactured in China and in Myanmar. Over 60% of oral AMT products had a shelf 
life at purchase of greater than 2 years and only 14.7% were expired. The median number of oral AMT tablets typi-
cally dispensed to treat malaria was two tablets, approximately one tenth of a full adult course. The median price of a 
50 mg tablet was $0.16.
Conclusions: Given the high availability and distribution of oral AMT, it is possible that Myanmar has become the last 
remaining viable market for any oral AMT in the region for manufacturers. National and international organizations 
need to act quickly and effectively to stop the production and distribution to both improve malaria control within 
Myanmar and reduce risk of artemisinin resistance spreading to India and Africa.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
While the World Health Organization (WHO) recom-
mends the use of intravenous and intramuscular arte-
misinins for treatment of severe malaria [1], the use of 
oral artemisinin-based monotherapies (AMT) is not 
recommended for any form of malaria treatment. Oral 
AMT is considered to be a major contributing factor to 
the development of malaria parasite resistance to arte-
misinin derivatives [2]. Since 2007, the WHO has urged 
regulatory authorities in malaria-endemic countries to 
take measures to halt the production and marketing of 
these oral monotherapies, and promote access to quality-
assured artemisinin-based combination therapies [3]. 
While many countries have adopted and enforced this 
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resolution, the global manufacturing and production 
of oral AMT continues [4]. In fact, recent market intel-
ligence data, generated by the ACTwatch project [5, 6], 
illustrates that oral AMT continues to be distributed 
and sold in some countries, particularly in the private 
sector. Findings from the project point to the persistent 
widespread availability and distribution of oral AMT 
in Myanmar, which accounts for the highest burden of 
malaria in the Greater Mekong Sub-region (GMS) and 
is notably considered an important probable origin and 
route of multi-drug resistance.
Oral artemisinin monotherapy was banned in Myan-
mar in 2012 by the Myanmar Food and Drug Administra-
tion (FDA). However, the regulatory policy permits oral 
AMT distributors with a valid 5-year import registration 
license awarded prior to the ban to continue to procure 
and sell this monotherapy within the country [7]. Given 
that oral AMT has a shelf life of 4  years from the time 
of manufacture, oral AMT medicines can be produced 
and imported until 2017 and could remain on the shelf 
until 2021. Indeed, outlet survey trend data from East-
ern Myanmar over the years have shown that despite a 
plethora of strategies to remove this from the market, 
oral artemisinin monotherapy commonly persists [7]. 
This has included the Artemisinin Monotherapy Replace-
ment (AMTR) project, which was designed to rapidly 
remove artemisinin monotherapies from the market by 
increasing private sector access to first-line subsidized 
artemisinin-based combination therapy (ACT) medi-
cines. Additional project activities targeted private sec-
tor providers (general retailers, pharmacies and itinerant 
drug vendors) located in Eastern Myanmar to encourage 
adoption of ACT.
In 2015, the ACTwatch project for the first time, 
implemented a national level outlet survey in Myanmar 
across four geographically diverse domains to provide 
a complete picture of the availability and distribution 
of anti-malarials in the private sector and among com-
munity health workers in the not-for profit sector. The 
objective of this paper is to provide timely, actionable 
evidence to inform urgently needed strategies to remove 
oral AMT from Myanmar’s marketplace. This paper 
describes what is currently known about the sale and dis-
tribution of oral artemisinin monotherapy and answers 
several questions, including (1) Where is artemisinin 
monotherapy available and distributed? (2) What types 
of products are available and distributed? (3) What are 
the provider practices regarding the re-supply and sale 
of oral artemisinin monotherapy? Evidence from the oral 
AMT market will point to recommendations for remov-
ing this medicine completely from the market in order 
to protect the efficacy of artemisinins in Myanmar and 
beyond.
Methods
All outlets with the potential to sell or distribute anti-
malarials and/or provide malaria blood testing were 
included in the sample. In Myanmar, these included com-
munity health workers, private for-profit health facili-
ties, pharmacies, general retail outlets, and itinerant drug 
vendors (see Additional file 1). The study was not able to 
gain access to government health facilities, namely public 
health facilities, and thus were excluded from the study.
The survey was conducted across four study domains: 
Eastern (where the AMTR project was implemented), 
Central, Western and Coastal areas of the country. A rep-
resentative sample of clusters (defined as wards in urban 
areas and village tracts in rural areas) were selected in 
each domain, using probability proportional to popula-
tion size (PPS). Between 180 and 240 urban wards and 
rural tracts in total were selected per domain. Within 
each selected ward/village tract, a census of all outlets 
with the potential to sell or distribute anti-malarials and/
or provide malaria blood testing was conducted. Outlets 
were eligible for a provider interview and a malaria prod-
uct audit if they met at least one of three study criteria: 
(1) one or more anti-malarials reportedly in stock the 
day of the survey; (2) one or more anti-malarials report-
edly in stock within the 3 months preceding the survey; 
and/or (3) provides malaria blood testing (microscopy or 
rapid diagnostic test [RDT]) at the time of the survey.
Outlets that met the screening criteria were invited 
to participate in the survey, and among providers that 
gave verbal informed consent, an audit of all available 
anti-malarial medicines and RDT was conducted. Anti-
malarial audit information included formulation, pack-
age size, brand name, active ingredients and strengths, 
manufacturer, country of manufacture, reported sale/dis-
tribution in the week preceding the survey, retail price, 
and wholesale price. Where oral artemisinin monother-
apy was found, an additional module was administered 
to understand the supply chain for this monotherapy. 
Questions included where the medicine was purchased, 
when the medicine was last purchased from the supplier, 
how many packages were purchased, wholesale price, the 
number of tablets typically dispensed, how many pack-
ages were currently in stock, and expiry dates for pack-
ages in stock. For all interviews a structured, paper-based 
questionnaire was administered. Data collection was 
implemented from August 18th, 2015 through January 
4th, 2016. Interviewer training consisted of standardized 
classroom presentations and exercises as well as a field 
exercise. Exams administered during training were used 
to select data collectors, supervisors, and quality-con-
trollers. Additional training was provided for supervisors 
and quality-controllers focused on field monitoring, veri-
fication visits, and census procedures.
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Analysis
All data cleaning and analysis was completed using Stata 
13.1 (©StataCorp, College Station, TX). Sampling weights 
were applied to account for variations in probability of 
selection, and standard error estimation accounted for 
clustering at the ward/village track level.
Standard ACTwatch indicator definitions have been 
reported elsewhere [5, 6, 8]. Briefly, anti-malarials identi-
fied during the outlet drug audit were classified according 
to information on drug formulation, active ingredients 
and strengths. Artemisinin monotherapies were fur-
ther classified as oral and non-oral, the latter including 
medicines recommended for the first-line treatment of 
severe malaria. Anti-malarial market composition was 
defined as the proportion of outlets of each type, or the 
proportion of outlets within each domain, among outlets 
with oral AMT in stock on the day of the survey. Mar-
ket share, or the relative distribution of the anti-malarials 
to individual consumers recorded in the drug audit, was 
standardized to allow meaningful comparisons between 
anti-malarials with different treatment courses and dif-
ferent formulations. The adult equivalent treatment dose 
(AETD) was defined as the amount of active ingredient 
required to treat an adult weighing 60  kg according to 
WHO treatment guidelines [1]. Provider reports on the 
amount of the drug sold or distributed during the week 
preceding the survey were used to calculate volumes 
according to type of anti-malarial. The volume of each 
drug was calculated as the number of AETDs that were 
reported to have been sold/distributed during the week 
preceding the survey. Measures of volume included all 
dosage forms to provide a complete assessment of anti-
malarial market share.
The price of oral AMT is reported as the median price 
per 50  mg tablet of oral AMT sold. This is a departure 
from the standard ACTwatch method of calculating 
price, which is the median price per one adult equiva-
lent treatment dose (AETD). Price was calculated in this 
manner to provide a more relevant price of oral AMT, 
given that most commonly this monotherapy is sold as 
one or two tablets, rather than a full course treatment of 
20 tablets. The type of outlets supplying oral AMT to ser-
vice delivery points was calculated as the percentage of 
outlets reportedly named by the provider as the distribu-
tor of the oral AMT product. Providers had the option to 
name more than one supplier/source.
Protection of human subjects
The 2015 outlet survey protocol received ethical approval 
from PSI’s Research Ethics Board, headquartered in 
Washington DC, USA and registered under the Office 
of Human Research Protections (OHRP FWA00009154, 
IRB#00006961).
Results
Availability
Table 1 shows a detailed breakdown of oral AMT avail-
ability at the outlet level across domains. A total of 3859 
outlets across all four geographic domains had an anti-
malarial in stock on the day of survey. Of these, 988 out-
lets had oral AMT in stock on the day of the survey, and 
217 had oral AMT within the past 3 months.
The national estimate for oral AMT availability on 
the day of the survey among anti-malarial stocking out-
lets was 17.3%. Observing domain differences, availabil-
ity was highest among outlets in the Western border at 
36.8% versus the Eastern domain (15.0%), Central domain 
(19.3%), and Coastal domain (10.7%). The percentage 
of outlets stocking oral AMT in the past 3  months but 
not on the day of the survey was 2.9% nationally and was 
comparable across domains.
Figures  1 and 2 illustrate the relative distribution of 
service delivery points for oral AMT stocking outlets, by 
domain and by outlet type. Figure 1 shows that in terms 
of absolute number of places where oral AMT medicines 
were available, most were categorized as private sector 
outlets. Over 90% of the oral AMT service delivery points 
comprised of private sector outlets: general retailers 
(49.4%), pharmacies (23.5%), and itinerant drug vendors 
(14.2%). The relative distribution of oral AMT-stocking 
outlets by outlet type was less than 10% for community 
health workers and private for-profit facilities (6.9 and 
6.1%, respectively). Of the 988 oral AMT-stocking outlets 
nationally, the Eastern area had the largest relative num-
ber of oral AMT-stocking outlets nationally at 35.3%, fol-
lowed by the Central area (32.7%). The relative number 
of oral AMT-stocking outlets was 23.0% in the Coastal 
domain and less than 10% in the Western domain (Fig. 2). 
Table 2 shows a breakdown of audited oral AMT prod-
ucts. Of the 1036 oral AMT products audited (Eastern, 
N = 308; Central, N = 166, Coastal, N = 180, Western, 
N  =  648), tablet formulation was either artemether 
(68 products) or artesunate (968 products). The most 
commonly audited oral AMT product was branded as 
 Artesunate®, manufactured by Mediplantex in Vietnam 
(n  =  834). Other common products included  Artem® 
by Kunming Pharmaceutical Corporation in China 
(n  =  26) and AA-Artemether® by AA medical prod-
ucts in Vietnam (n  =  22). All artesunate tablet prod-
ucts with known product information had a strength 
of 50  mg (n  =  929) whereas artemether tablets with 
known product information were found in strengths of 
40  mg (n =  33) and 50  mg (n =  24). All branded oral 
AMT products came in a pack size of 12 tablets with 
the exception of  Artesunate® manufactured by Myan-
mar Pharmaceutical Factory or Tatmadaw Pharmaceuti-
cal Factory in Myanmar that were found in tins of 100 
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tablets (n = 14). There were 50 oral AMT products that 
were found as loose tablets stored in containers (plas-
tic tins) without product information (brand, manufac-
turer, and country of manufacturer), represented by two 
dashes in the table.
The characteristics of oral AMT supply and demand 
are shown in Table  3. According to provider reporting, 
most oral AMT products were obtained from a pharmacy 
(53.5%) or a fixed-location medicine wholesale outlet 
(40.0%). Only 8.1% of oral AMT products were obtained 
from some other type of supplier; the most common 
other types of suppliers cited were mobile distributor, vil-
lage buyer, rural health centre, or ‘floating shops’ which 
were reportedly found on boats that traverse local riv-
ers. Over half (53.1%) of oral AMT products had been 
obtained from a supplier within the past 3 months. The 
median number of packages in stock on the day of the 
survey was 1.0 (IQR = 0.4–2.4). Over two-thirds (68.2%) 
of oral AMT products were reportedly requested by 
name by consumers.
Table  4 displays the breakdown of oral AMT prod-
uct characteristics. Of the 1036 oral AMT products in 
stock on the day of the survey, 75.0% was  Artesunate®, 
manufactured by Mediplantex in Vietnam. Another 8.0% 
of oral AMT products were manufactured by AA medi-
cal products in Vietnam and were either AA-Artesu-
nat® (n  =  17) or AA-Artemether® (n  =  22). Kunming 
N=988
Eastern
Central
Western
Coastal
Fig. 2 Distribution of oral AMT stocking outlets, by domain
Table 2 Product catalogue of the types and number of oral AMT products
Country of manufacturer Manufacturer Brand name Strength (mg) Package size N
Artemether tablets 68
 China Kunming Pharmaceutical Corporation (KPC) Artem 40 12 26
Chongqing Holley Pharmaceutical Co. Ltd. Artemether 40 12 7
 Vietnam AA medical products AA-Artemether 50 12 22
 – – Artemether 50 12 2
 – – Artemether – – 11
Artesunate tablets 968
 China Guilin Pharmaceutical Co. Ltd. 50 12 2
Jiangxi Xierkangtai Pharmaceutical Co. Ltd. 50 12 1
Zhangfeng Pharmaceutical Factory 50 12 17
Zhejiang Holley Nanhu Pharmaceutical Co. Ltd. Arthesis 50 mg 50 12 12
 Myanmar Myanmar/Tatmadaw Pharmaceutical Factory 50 100 14
 Vietnam AA medical products AA-Artesunat 50 12 17
Central Pharmaceutical Factory No. 1 Artesunate 50 12 2
Mediplantex 50 12 834
Medopharm 50 12 2
Mekophar Chemical Products 50 12 1
Traphaco Traphasunat 50 mg 50 12 9
 – – Artesunate 50 12 18
 – – Artesunate – – 39
Total oral AMT 1036
N=988
Community health worker
Private for profit health facility
Pharmacy
General retailer
Itinerant drug vendor
Fig. 1 Market compostion  of oral AMT-stocking outlets, by outlet 
type
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Pharmaceutical Corporation in China was responsible 
for manufacturing 2.6% of oral AMT products (all were 
 Artem®) found in Myanmar in 2015.
At the time of the survey, of the 912 oral AMT prod-
ucts with known expiry dates, 14.7% of oral AMT prod-
ucts audited were expired and slightly less than a quarter 
(23.6%) had less than a year to expiry. Over 60% of oral 
AMT products found at the time of the survey still had 
a shelf life of greater than 2  years. When broken down 
by manufacturer, 72.5% of  Artesunate® by Mediplantex 
had a shelf life of greater than 2 years. Over 85% of prod-
ucts manufactured by AA Medical were expired or due 
to expire within the year, and almost 85% of oral AMT 
that had been manufactured in China was expired at the 
time of the survey. The median number of oral AMT tab-
lets typically dispensed to treat malaria in an adult was 
two tablets, approximately 10% of an AETD, and had an 
IQR of 1.2–7.2 tablets. The median price of a 50 mg tab-
let after the median 30.1% retail percentage mark-up was 
$0.16. This equated to a treatment price of $0.32 for a 
typical oral AMT treatment dose.
Figure 3 shows the national level anti-malarial market 
share for each type of anti-malarial distributed: ACT, 
chloroquine, other non-artemisinin therapies, and non-
oral and oral artemisinin monotherapies. Figure  4 illus-
trates the oral AMT market share for artemether and 
artesunate and for major brand names. Sale or distribu-
tion of oral AMT comprised 14.8% of the anti-malarial 
market nationally in 2015. Of all oral AMT sold or dis-
tributed, 79.9% was labelled  Artesunate® and manufac-
tured by Mediplantex in Vietnam. Other products that 
were sold in low volumes included  Artesunate® by Cen-
tral Pharmaceutical Company in Vietnam, and  Artem® by 
Kunming Pharmaceutical Corporation in China. Around 
5% of the oral AMT products had unknown brand and 
manufacturing information.
Table 3 Characteristics of oral AMT supply and demand
*Oral AMT products in stock on the day of the survey or reportedly in stock in 
the past three months
National
% (95% CI)
Proportion of oral AMT products that were 
reportedly obtained from
N = 1335
 Pharmacy 53.5 (47.3, 59.7)
 Fixed-location medicine wholesale outlet 40.0 (33.5, 46.6)
 Other (mobile distributor, village buyer, rural 
health centres, and ‘floating shops’)
8.1 (5.3, 10.9)
Proportion of oral AMT products that were 
reportedly obtained from a supplier within 
the past 3 months
53.1 (47.1, 59.0)
Median [IQR](N)
Among oral AMT products, median
 Number of oral AMT packages in stock on the 
day of the survey
1.0 [0.4–2.4](1302)
% (95% CI)
Proportion of oral AMT products* that
 Were reportedly requested by name by 
consumers
68.2 (63.0, 73.4)
Table 4 Characteristics of oral AMT products: expiry, man-
ufacturer, and price
Ψ There were 124 oral AMT products missing expiry date information; these 
were not included in thedenominator
% (95% CI)
Proportion of oral AMT products
 Expiry  datesΨ N = 912
  Expired at the time of the survey 14.7 (9.8, 19.7)
  Less than 1 year to expiry 23.6 (18.3, 29.0)
  1–2 years to expiry 9.7 (5.7, 13.8)
  Greater than 2 years to expiry 60.4 (54.2, 66.6)
 Manufacturer N = 1036
  Mediplantex (Vietnam) 75.0 (68.9, 81.1)
  AA medical products (Vietnam) 8.0 (4.7, 11.2)
  Kunming Pharmaceutical Corporation 
(China)
2.6 (1.0, 4.2)
  Other 14.4 (10.1, 18.7)
Median [IQR](N)
Among oral AMT products, median
 Retail price per 50 mg tablet sold to 
patients
$0.16 [0.12–0.18](989)
 Retail percentage mark-up 30.1% [14.9–54.2%](817)
 Number of 50 mg tablets typically dis-
pensed to treat malaria in an adult
2 [1.2–7.2](928)
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Discussion
This study provided timely, actionable evidence to 
address persistent sale and distribution of oral AMT in 
Myanmar. The results of the study illustrate widespread 
availability and distribution of oral AMT across Myan-
mar. Strategies to confiscate this medicine from the mar-
ketplace, and to scale-up existing efforts to completely 
remove this monotherapy are urgently needed. Lessons 
learnt from other countries can be applied to ensure suc-
cessful strategies, though must be adapted to meet Myan-
mar’s ethnically diverse and vastly different geographical 
landscape.
Where is oral artemisinin monotherapy available?
Findings from the 2015 ACTwatch outlet survey found 
a high number of oral artemisinin monotherapies, with 
over 1000 audited products representing over 10% of 
all anti-malarial medicines audited. The findings illus-
trate how the private sector remains responsible for the 
majority of oral AMT distribution in Myanmar. General 
retailers, pharmacies, and itinerant drug vendors were 
the outlet types most commonly responsible for stock-
ing oral AMT. This is consistent with 2015 market share 
observations that show oral AMT market share was 
markedly higher in the total private sector (19.6%) ver-
sus community health workers (3.8%) [9]. Future strate-
gies to address the removal of this medicine must target 
and engage with the private sector, including pharmacies, 
general retailers and itinerant drug vendors.
At the national level, one in five anti-malarial-stock-
ing outlets had oral AMT in stock. Close to half of anti-
malarial-stocking private sector outlets in the Western 
domain were stocking oral AMT, pointing to widespread 
availability in areas next to the Indian border. Although 
the oral-AMT availability was highest in the Western 
domain, the majority of oral AMT-stocking outlets were 
located in the more populous Eastern and Central areas 
of the country. Oral AMT availability across the coun-
try is of grave concern given Myanmar is considered an 
important probable origin and route of spread of multi-
drug resistance to other parts of the world.
The results are somewhat surprising in Eastern Myan-
mar, given that several strategies have been implemented 
in this area since 2012 to contain the spread of arte-
misinin drug resistance [10]. One of the key strategies 
has been a project to remove oral AMT from the private 
sector and replace it with quality-assured ACT  through 
the AMTR project. In 2012 the main distributor of oral 
AMT, AA Pharmaceuticals, was identified and engaged 
in an agreement to replace sales of oral AMT with first-
line, subsidized ACT. Additional strategies included 
behaviour change communication (BCC) to increase 
demand for ACT, coupled with intensive pharmaceutical 
detailing operations, targeting general retailers, pharma-
cies and itinerant drug vendors through product promot-
ers to facilitate ACT uptake in the supply chain. These 
efforts were coupled by the significant role of the Myan-
mar FDA, which has played an important role in trying to 
enforce the ban on oral AMT registration and importa-
tion despite limited resources and challenges in gaining 
access to border control areas. This included high-level 
advocacy with the military-operated Tatmadaw Phar-
maceutical to halt the manufacturing of oral AMT in the 
country in late 2015. It is expected that the last batch of 
oral AMT manufactured by Tatmadaw was produced in 
late 2015 as an agreement was drawn up between the 
Ministry of Health (MoH) and the Ministry of Defense. 
Indeed, this locally manufactured product was rarely 
audited in the survey.
Despite these efforts by the government and interna-
tional NGOs, market trend data from the Eastern part 
of Myanmar showed that while availability of oral AMT 
has declined over the years, between 2014 and the cur-
rent study round, an increase in availability was observed 
among general retailers, pharmacies and itinerant drug 
vendors from 10.3% in 2014 to 27.2%. That said, avail-
ability of oral AMT was lowest in the Eastern domain 
as compared to other domains, pointing to the success 
of the many strategies. It is postulated that in 2015 there 
may have been a final push by distributors to get rid of 
any last remaining stock of oral AMT, before it expired. 
Perhaps more likely, this could reflect a 3–4 month stock-
out of ACT medicines during the peak malaria transmis-
sion season in 2015. Frequent changes in key leadership 
positions within the Ministry of Health resulted in an 
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unexpected delay in obtaining approval to import ACT 
medicines into the country  for the AMTR project, indi-
cating the importance of constant supply of ACT to 
ensure universal coverage and reduce the distribution of 
unwanted medicines.
Other higher level, multi-pronged strategies may be 
considered that speak to enforcement and regulation 
of the ban. Strategies have recently been implemented 
in Cambodia resulting in the successful removal of 
oral AMT from the private sector [11]. These included 
increasing private sector access to subsidized first-line 
ACT. To enforce the ban on oral AMT instituted in 
2008, strategies have included the recruitment of officials 
known as the ‘Justice Police’, as well as training of over 
400 police to identify oral AMT at service delivery points 
and actively enforce the ban by removing products and 
sanctioning outlets. The government also used mystery 
clients to further identify outlets selling any oral AMT, 
and instituted a system of licensing drug outlets and 
using the Justice Police to regularly check for and confis-
cate fake, substandard or banned drugs. In addition, an 
international collaboration led by INTERPOL succeeded 
in interrupting one trade route of a major Chinese pro-
ducer of fake artemisinin that had flooded the market in 
Cambodia [12]. These efforts were supported by a com-
munication campaign to educate private providers and 
consumers about the dangers of oral AMT. Similar suc-
cess stories have also been observed in the Lao Peoples 
Democratic Republic, where the availability of oral AMT 
significantly decreased from 22.9% in southern Laos in 
2003 to 4.8% in 2012 [13]. This was attributed to several 
strategies to improve case management in the private 
sector, but also reflected changes to treatment policy, 
trading agreements with manufacturers of oral AMT, and 
amendments to the law on Drugs and Medical Products 
to ensure adequate registration, distribution, and supply 
of all medicines.
Such strategies may be applicable in Myanmar to 
ensure effective and immediate removal of oral AMT 
from the marketplace. To-date, there has been no offi-
cial communication on oral AMT in Myanmar, includ-
ing a lack of communication on banned products and 
the dangers of continuing use of such products. Com-
munication campaigns could be an important first step to 
tackle the widespread availability of oral AMT. However, 
these interventions must be couched with the reality that 
Myanmar has over 100 ethnic groups, with many differ-
ent languages, which can pose a challenge for clear and 
effective communication. Future strategies must also con-
sider that many areas of Myanmar are under conflict and 
controlled by ethnic armed groups, for which the central 
government and local and international NGOs have vari-
able access. The political and geographical diversity must 
be considered and overcome to ensure effective imple-
mentation and successful behaviour change strategies.
Promisingly, the Myanmar FDA underwent a major 
restructuring of their department in 2014 and the 
Government of Myanmar has allocated considerable 
resources to improve the infrastructure, including an 
expansion of human resources. In addition to the Central 
level, the FDA now has officers at the State and Division 
level, allowing for greater national influence. This pre-
sents an opportunity for implementers to work closely 
with the FDA as a means to strengthen and regulate the 
sale of oral AMT and educate wholesale providers about 
the dangers of oral AMT.
What types of products are found on the shelf and being 
distributed?
All oral AMT products found in Myanmar were manu-
factured in either Vietnam, China, or locally in Myan-
mar, with the vast majority having been manufactured 
in Vietnam. Three-quarters of the available products 
were  Artesunate®, manufactured by Mediplantex in 
Vietnam. This was also the most commonly distributed 
product by far, capturing over 80% of the market share. 
These products were stamped with ‘GMP-WHO’ (Good 
Manufacturing Practices-World Health Organization), 
misleadingly indicating to both patients and providers 
that these drugs are recommended by the WHO based 
on the implicit level of quality conferred by the manufac-
turer’s GMP status. This is of further concern given that 
‘GMP-WHO’ is a fake label and does not exist as a quality 
standard. Additionally, the instructions were only in Chi-
nese and English—with no Myanmar translation—and 
also included vague contraindications, such as ‘pregnant 
women should use the drug carefully’.
With many products having a shelf life of greater than 
2 years at the time of the survey, and some products with 
an import registration number, this confirms that there 
has been both recent manufacturing of the product as 
well as recent importation. Indeed, direct communica-
tion with the manufacturer confirmed that oral AMT 
was still in production in late 2016, with two strengths 
(50 and 100 mg), with a minimum order of 20,000 tablets 
[14].
The findings from the product audit speak to three 
important conclusions regarding importation and future 
strategies to remove the medicine. First, the recent 
import of this medicine confirms that there are sig-
nificant gaps or loopholes in the regulatory policy sur-
rounding oral AMT, either that the ban on import is not 
being enforced, or simply that the import of oral AMT 
products with a registration license is still legal in Myan-
mar. Myanmar can potentially expect further import 
of this medicine until the manufacturer decides to stop 
Page 10 of 12ACTwatch Group et al. Malar J  (2017) 16:170 
producing it. Second, as no other single brand had more 
than three percent of the market share, another key con-
clusion from this study is that currently a single product 
and manufacturer dominates the market. This provides 
an opportunity, not dissimilar from that of the situation 
with a key supplier identified in the Eastern part of the 
country several years ago [10], to target the top of the 
supply chain and halt further large-scale distribution 
of this product. Finally, while oral AMT manufactur-
ers were limited to three countries, the wider range of 
brand names and one-off products, seems to suggest that 
oral AMT is not only being imported under official sup-
ply chains (e.g. products with registration numbers) but 
through unofficial channels across the border. Increased 
regulation of borders or licensing of medicines will be 
necessary to ensure that removal of oral AMT is sus-
tained, which could be addressed nationally by explicit 
communication from the FDA to wholesalers regarding 
the dangers of oral AMT. This should also be addressed 
by WHO as part of their policy to halt the manufacturing 
of oral AMT. On a yearly basis, WHO routinely reaches 
out to manufacturers of oral AMT and asks them to sign 
agreements to stop production of this medicine [4].
What are the provider practices regarding the re‑supply 
and sale of oral artemisinin monotherapy?
Oral AMT was reportedly obtained by providers from a 
limited number of supplier types. Pharmacies and fixed-
location medicine wholesale outlets were the supplier 
for 93.0% of available products. Most outlets had a small 
number of oral AMT packages in stock and reported 
fairly frequent re-stocking with small volume purchases. 
The limited number of supplier types and minimal 
amount of oral AMT products in stock at the lowest level 
suggests that the oral AMT supply chain could be rapidly 
disrupted. This would additionally benefit from several 
strategies mentioned previously to ensure tightened reg-
ulation of the policy.
As providers typically had only one or two packages 
in stock, it is perhaps not a surprise that oral AMT was 
most often distributed in doses of approximately two 
tablets, making it feasible for a provider to treat up to six 
patients with a 12-tablet package. Sub-optimal dosing of 
oral AMT medicines is particularly rampant throughout 
the private sector. This is not only unsafe for the patient, 
but also dangerous over time as the selection pressure 
on parasites to develop resistance to artemisinin is quite 
high [15]. Evidence of artemisinin-resistance is now 
prevalent throughout much of Myanmar where malaria 
is endemic and the spread of molecular markers across 
Myanmar has now been detected on the border with 
India [16]. Continued distribution of oral AMT at such 
a low dosage will further exacerbate the prevalence of 
artemisinin resistant malaria parasites in Myanmar and 
increase the likelihood of spread of artemisinin resistance 
into China, India, and westward [17].
More than two-thirds of oral AMT products were 
reportedly requested by name by patients, suggesting 
that consumer demand may also play a role. A recent 
study that investigated factors associated with outlet pro-
viders who stock oral AMT in Myanmar, found that the 
odds of stocking oral AMT was almost four times higher 
among providers who report that customers ask for this 
by name compared to providers that report costumers do 
not demand the medicine by name [18]. Evidence from 
other countries also supports this, where administra-
tion of the first-line treatment seems to depend on what 
patients demand [19]. This points to the need for strat-
egies that not only focus on provider behaviour change, 
but also address patient preferences and awareness of 
what medicine to ask for. As such, targeting provider 
knowledge, preferences and behaviour alone may not be 
sufficient to drive uptake of the first-line treatment [20]. 
To help remove oral AMT from the market, there is likely 
a need for supporting interventions to drive consumer 
awareness and demand for first-line treatment [21].
The policy implications from this paper are clear. The 
production of oral AMT by Vietnamese manufacturers 
must end. The continued manufacturing and distribu-
tion not only threatens efforts by WHO efforts to com-
bat artemisinin resistance, but also threatens malaria 
control efforts in Africa. It is both discouraging and dis-
heartening that while oral AMT consumption is banned 
in Vietnam, manufacturing and exportation is however 
permitted [WWARN, pers. comm.]. These disappoint-
ing actions should act as a rallying call to the global com-
munity, especially given the financial investment and 
international and national commitment to preserve the 
efficacy of artemisinins and ultimately save lives. Con-
tinued production of oral AMT should be raised before 
the World Health Assembly as a means to gather further 
momentum by the international community to stop pro-
duction of this dangerous anti-malarial.
Finally, as the sale of oral AMT is typically just two tab-
lets, the price of a typical dose has implications for pric-
ing quality-assured recommended alternatives. While a 
private sector subsidy has reduced the price of quality-
assured ACT in Myanmar, a typical dose of oral AMT 
remains a less expensive option for a patient and pro-
vides a greater profit margin for the provider than first-
line ACT for treatment. The wholesale to retail markup 
of oral AMT was much higher than that of an ACT in 
the private sector: 30.2 versus 20.0% for ACT in the con-
text of an ACT subsidy programme [7]. Coupled with the 
knowledge that oral AMT shelf life is also double that 
of ACT (approximately 4 versus 2  years, respectively) 
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[10], evidence suggests a number of financial incentives 
for providers to stock and sell this monotherapy over 
an ACT. Furthermore, the median treatment price for 
a typical oral AMT treatment dose of two tablets was 
$0.32. This is comparable, and is in fact more than 10% 
less expensive than the median price of $0.36 for ACT in 
Myanmar, suggesting that oral AMT may be more afford-
able to patients. Consumer price and potential profit for 
providers may be factors influencing demand for oral 
AMT in Myanmar, as has been identified in other set-
tings introducing ACT in competition with cheaper anti-
malarial alternatives [8, 22, 23]. Increased provider and 
consumer knowledge on the differing treatment guide-
lines between Plasmodium falciparum and Plasmodium 
vivax malaria, could create market demand for appro-
priate treatment for each malaria species according to 
national guidelines.
Limitations
The 2015 ACTwatch Outlet Survey in Myanmar was 
not designed to capture the entire anti-malarial mar-
ket or to map the entire supply chain for oral AMT and 
for all anti-malarial medicines. The study was limited to 
the private sector and community health workers—gov-
ernment facilities were not visited. However, it is likely 
that oral AMT availability and distribution are relatively 
low in government health facilities. This study used the 
adult equivalent treatment dose (AETD) for the unit of 
analysis in calculating relative market share for each type 
of anti-malarial medicine. However, oral AMT is most 
typically sold in a treatment dose of two tablets instead 
of the full AETD of about 20 tablets. As such, the pro-
portion of patients that are treated with oral AMT rela-
tive to other types of anti-malarials is likely much higher 
than the market share estimated using AETDs distrib-
uted. Given the widespread availability and distribution 
of oral AMT, further study is needed to understand the 
supply chain at various levels. This is particularly true 
at higher levels in order to understand where and under 
what guise oral AMT is imported. Additional surveys in 
key areas of China or along the India border would be 
particularly beneficial. The study also did not assess con-
sumer demand or behaviour directly. Further studies that 
engage the patient, especially in a qualitative manner, are 
also necessary to inform effective strategies to address 
consumer knowledge and behaviour.
Conclusion
Given the high availability and distribution of oral AMT, 
it is possible that Myanmar has become the last remain-
ing viable market for any oral AMT in the region that is 
not expired or is still being manufactured. This could be 
due to loopholes in Myanmar’s regulatory policy and/or 
stringent regulations in the manufacturing country that 
do not permit local sale of oral AMT. Other factors that 
contribute to the uptake and ongoing distribution of this 
medicine speak to the long shelf-life of the product, pro-
vider dispensing practices, price and consumer demand. 
Urgent action is required to stop the manufacturing, sale 
and distribution of this medicine to protect the efficacy 
of ACT and curb the spread of multi-drug resistant para-
sites. A multi-pronged approach is needed to address 
the problem. Targeting suppliers at the top of the sup-
ply chain, improving and expanding upon BCC activi-
ties for both the provider and consumer, and demand 
for appropriate medicines are all crucial. International 
advocacy is also urgently needed to stop the manufactur-
ing and exportation of oral AMT in Vietnam and China, 
and advocacy measures by WHO are needed to encour-
age manufacturers to halt production. National policy 
changes that ban the full import, distribution, and sale 
of oral AMT and ultimately implementation of a pro-
gramme for removal of oral AMT from the market would 
create a far more conducive environment for the support 
of these activities.
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